- Conditions
- Age-Related Macular Degeneration
- Interventions
- Palomid 529
- Drug
- Lead sponsor
- Paloma Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Valeda Light Delivery System
- Device
- Lead sponsor
- LumiThera, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- combination ranibizumab + bromfenac, ranibizumab injection alone
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cataract, Macular Degeneration
- Interventions
- selenium, vitamin E, vitamin E placebo, selenium placebo
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 50 Years to 120 Years · Male only
- Enrollment
- 13,475 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Age-related Macular Degeneration
- Interventions
- Atorvastatin 80mg
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Macular Degeneration
- Interventions
- Rheopheresis blood filtration
- Device
- Lead sponsor
- OccuLogix
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2005
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 4 more
- Conditions
- Geographic Atrophy of the Macula
- Interventions
- GAL-101, Placebo
- Drug
- Lead sponsor
- Galimedix Therapeutics Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Drug
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- IBI-20089/Lucentis
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration
- Interventions
- SKG0106
- Genetic
- Lead sponsor
- Skyline Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SKG0106
- Genetic
- Lead sponsor
- Skyline Therapeutics (US) Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- St. Petersburg, Florida • Boston, Massachusetts • Katy, Texas + 1 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- RPESC-RPE-4W
- Biological
- Lead sponsor
- Luxa Biotechnology, LLC
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Palo Alto, California • Ann Arbor, Michigan
- Conditions
- Macular Degeneration, Diabetic Retinopathy
- Interventions
- TG100801
- Drug
- Lead sponsor
- TargeGen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Interventions
- SB-007
- Genetic
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- AGN-150998, ranibizumab, Sham Injection
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- AMD
- Interventions
- Implantable Miniature Telescope
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2028
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 12 more
- Conditions
- Geographic Atrophy
- Interventions
- Vonaprument, Sham Administration
- Drug · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 71
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
- Conditions
- Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
- Interventions
- Not listed
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- San Diego, California • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Marietta, Georgia • Lexington, Kentucky • Glen Burnie, Maryland + 4 more
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 56 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Retinal Diseases, Stargardt's Disease, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 4
- States / cities
- Hilo, Hawaii • Honolulu, Hawaii • Kahului, Hawaii + 1 more
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- aflibercept 8 mg PFS
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • The Woodlands, Texas
- Conditions
- Diabetic Retinopathy, Macular Degeneration
- Interventions
- intravitreal injection of infliximab
- Drug
- Lead sponsor
- Retina Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Slingerlands, New York